Kaufman Rossin Wealth’s BioMarin Pharmaceuticals BMRN Stock Holding History

Kaufman Rossin Wealth’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	–	Sell	-4,568	Closed	-$247K	–	161
2025 Q3	$247K	Buy	+4,568	New	+$261K	0.14%	114
2025 Q2	–	Sell	-6,519	Closed	-$461K	–	150
2025 Q1	$461K	Buy	+6,519	New	+$439K	0.33%	45

Other funds holding BMRN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Norges Bank Oslo, Norway $935B AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Kaufman Rossin Wealth's BMRN Position: Q4 2025 in Review

Kaufman Rossin Wealth sold out of BioMarin Pharmaceuticals (BMRN) in Q4 2025, closing a stake of 4,568 shares — an estimated $247K sold.

Kaufman Rossin Wealth first reported a position in BMRN in Q1 2025 and held it in 2 quarters. The position peaked at $461K in Q1 2025. 538 funds tracked by Wall St. Rank hold BMRN as of Q4 2025.

Kaufman Rossin Wealth reported no remaining BioMarin Pharmaceuticals position as of Q4 2025 after selling out during the quarter.
Kaufman Rossin Wealth sold 4,568 BioMarin Pharmaceuticals shares in Q4 2025, an estimated $247K.
Kaufman Rossin Wealth first reported a position in BioMarin Pharmaceuticals in Q1 2025 and held it in 2 quarters.
Kaufman Rossin Wealth's BioMarin Pharmaceuticals position peaked at $461K in Q1 2025.
538 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q4 2025.

Based on Kaufman Rossin Wealth's 13F filing for Q4 2025, filed 14 Jan 2026.